Strathprints logo
Strathprints Home | Open Access | Browse | Search | User area | Copyright | Help | Library Home | SUPrimo

Inhibition of cell growth by lovastatin

Winn, P.L. and Kelso, K. and Grant, M.H. (2004) Inhibition of cell growth by lovastatin. Toxicology, 202 (1-2). pp. 106-107. ISSN 0300-483X

Full text not available in this repository. (Request a copy from the Strathclyde author)

Abstract

Lovastatin has been shown to be a potent inhibitor of smooth muscle cell (SMC) growth (Liao et al., 2002; Mattingly et al., 2002). The drug is a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. By inhibiting mevalonate (MVA) synthesis, lovastatin prevents the synthesis of isoprenoid intermediates which serve as lipid attachments for post-translational modification of various cell signalling proteins (Munro et al., 1994). Ras and Rho B proteins are major substrates for post-translational modification by isoprenylation. Since they regulate cell growth, studies have suggested lovastatin inhibits DNA synthesis and SMC growth by inhibiting isoprenylation of key signalling proteins (Raiteri et al., 1997). The aim of our study was to find out if the inhibition of SMC growth by lovastatin is caused by inhibition of HMG-CoA and could therefore be reversed by MVA.

Item type: Article
ID code: 39086
Keywords: lovastatin, cell growth, smooth muscle cell , Pharmacy and materia medica, Toxicology
Subjects: Medicine > Pharmacy and materia medica
Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences > Physiology and Pharmacology
Faculty of Engineering > Bioengineering
Related URLs:
    Depositing user: Pure Administrator
    Date Deposited: 11 Apr 2012 14:58
    Last modified: 04 Sep 2014 19:38
    URI: http://strathprints.strath.ac.uk/id/eprint/39086

    Actions (login required)

    View Item